help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Russo, L.
Right arrow Articles by Moore, W. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Russo, L.
Right arrow Articles by Moore, W. V.

Journal of Clinical Endocrinology & Metabolism, Vol 55, 1003-1006, Copyright © 1982 by Endocrine Society

ARTICLES

A comparison of subcutaneous and intramuscular administration of human growth hormone in the therapy of growth hormone deficiency

L Russo and WV Moore

The sc and im administration of human GH (hGH) was compared in the therapy of GH deficiency. The peak and integrated concentrations of hGH in the plasma of the patients were similar after sc and im injection of an initial dose (0.1 U/kg) of hGH. The peak hGH concentration occurred at 2 h in both groups. The posttreatment height velocity and the change in height velocity at 3-month intervals were also similar in the im and sc groups. The somatomedin generation test resulted in a higher mean peak of somatomedin C after sc injection; however, if the individual peaks of somatomedin C were averaged, there was no difference between sc and im injection. A cross-over at 9 months of therapy to determine patient acceptance of im vs. sc injections indicated overwhelming acceptance of the sc route. The antibody responses to hGH were similar in both groups. We conclude that sc injection of hGH is an effective and safe mode of therapy for GH deficiency. The lipoatrophy that occurred infrequently at the injection site can be eliminated by rotation of sites. Subcutaneous administration of hGH will be more acceptable by the patients with less pain and less noncompliance.


This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
A. Keller, Z. Wu, J. Kratzsch, E. Keller, W. F Blum, A. Kniess, R. Preiss, J. Teichert, C. J Strasburger, and M. Bidlingmaier
Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration
Eur. J. Endocrinol., June 1, 2007; 156(6): 647 - 653.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. F. Kemp, P. J. Fielder, K. M. Attie, S. L. Blethen, E. O. Reiter, K. M. Ford, M. Marian, L. N. Dao, H. J. Lee, and P. Saenger
Pharmacokinetic and Pharmacodynamic Characteristics of a Long-Acting Growth Hormone (GH) Preparation (Nutropin Depot) in GH-Deficient Children
J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3234 - 3240.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1982 by The Endocrine Society